Search results (41)
« Back to Latest newsOxford University and King’s College London Join IMPACT Network Study to Advance Understanding of Profound Autism
24 June 2026
The University of Oxford and King’s College London (King’s) have joined the Innovative Medicine and Precision Approaches to Clinical Trials (IMPACT) Network, an international collaboration of sites working together to accelerate clinical trial readiness and therapeutic development for autism through a large-scale natural history and clinical endpoint study.
Scientists in the Department of Paediatrics discover antibody combinations that block over 90% of malaria parasite growth
12 June 2026
In an important discovery for the next-generation of malaria vaccines, University of Oxford researchers in the Department of Paediatrics, in collaboration with the Scripps Institute, have identified how antibodies can be over 90% effective at preventing malaria parasites from growing in certain combinations.
Oxford Bundibugyo ebolavirus vaccine candidate receives CEPI backing
1 June 2026
The Coalition for Epidemic Preparedness Innovations (CEPI) has announced today that it will urgently accelerate the development of three investigational vaccines targeting the Bundibugyo ebolavirus that has caused a rapidly spreading epidemic in the Democratic Republic of the Congo (DRC) and neighbouring Uganda, including one being developed by the Oxford Vaccine Group at the University of Oxford.
Statement on vaccine efforts relating to the Bundibugyo Ebolavirus outbreak in the DRC
22 May 2026
In response to the current Bundibugyo Ebolavirus outbreak in the Democratic Republic of the Congo, the Oxford Vaccine Group (OVG) is working urgently with Oxford’s own Clinical BioManufacturing Facility and the Serum Institute of India Pvt. Ltd. (SIIPL), to rapidly produce and scale doses of our ChAdOx-based monovalent Bundibugyo Ebolavirus candidate vaccine, ChAdOx1 BDBV.
Breakthrough study moves newborn screening for SMA towards nationwide rollout
15 May 2026
A major national study led by researchers in the Department of Paediatrics, to evaluate newborn screening for spinal muscular atrophy (SMA) has been funded by the National Institute for Health and Care Research (NIHR), marking a significant milestone towards the potential introduction of SMA screening across the UK.
New clinical trials begin in Burkina Faso
23 February 2026
Vaccinations have started at the Institut de Recherche en Sciences de la Santé – Clinical Research Unit of Nanoro (IRSS-URCN), Burkina Faso for two clinical trials to assess the blood-stage malaria vaccine candidates R78C and RH5.1 with Matrix-M (developed by the Draper Lab in the Department of Paediatrics), in combination with the R21/Matrix-M vaccine, which targets the earlier liver-stage. The trials are sponsored by the University of Oxford (UOXF), UK, with the European Vaccine Initiative (EVI) acting as both a co-funder and collaborator. These exciting studies are expected to provide proof-of-concept for the use of a multi-stage vaccine to extend the protection against malaria and help lead to future efforts to eliminate it by targeting two stages of the parasite’s life-cycle.
World's first Phase II Nipah virus vaccine trial launch
9 December 2025
The University of Oxford has launched the world’s first Phase II clinical trial of a Nipah virus vaccine candidate.
First Volunteer Receives Lassa Fever Vaccine in Cutting-edge Oxford Trial
4 December 2025
The first volunteer has received a dose in a first-in-human trial of Oxford’s Lassa vaccine, marking a major milestone in the fight against the deadly virus. The trial, conducted by the Oxford Vaccine Group, and funded by the Coalition for Epidemic Preparedness Innovations (CEPI), will assess the safety and immune response of the ChAdOx1 Lassa vaccine. 31 people aged 18-55 will participate in the trial in total.
Oxford-led study shows vaccine protection against Salmonella Paratyphi A
30 October 2025
Results from a study published today in The New England Journal of Medicine show that a vaccine can protect people against Salmonella Paratyphi A infection.
Major investment puts UK universities at the forefront of groundbreaking lymph node research
14 October 2025
Three UK universities have been granted over £1.7m by the Medical Research Council (MRC) to establish a network of lymph node research centres across the UK. The novel LEGACY IIII Network (Lymph nodE single cell Genomics AnCestrY immunity, infection, inflammation and immunisation) will be co-led by the Universities of Oxford, Cardiff and Newcastle and will establish ten specialist lymph node research centres across the country.
New jab protects babies from serious lung infection, study shows
23 July 2025
Vaccination of pregnant women has been linked to a drop in newborns being admitted to hospital with a serious lung infection, research suggests.
Oxford vaccine against deadly Nipah virus granted EMA PRIME designation for the first time
9 June 2025
The University of Oxford’s vaccine to protect people from deadly Nipah virus has been granted support from the PRIority MEdicines (PRIME) scheme offered by Europe’s medicines regulator, the European Medicines Agency (EMA). It is the first UK academic institution to be awarded this designation.
New MenB Vaccine Shows Promise in Early-Stage Trial Results
19 May 2025
The outcome of a trial published in Science Translational Medicine, shows encouraging results for a new vaccine targeting group B meningococcus (MenB), a significant cause of meningococcal disease worldwide, and establishes proof-of-concept in humans that a gene-based vaccine platform can induce protective antibody responses against bacteria.
Trial results for first vaccine against blood-stage malaria show it is well-tolerated and offers effective protection
10 December 2024
Results of a clinical trial into a new malaria vaccine candidate (RH5.1/Matrix-M) show it is well-tolerated and offers effective protection against the blood-stage of the disease – the first inoculation to do so.
Typhoid vaccine trial confirms sustained protection for older children
10 October 2024
A single dose of typhoid conjugate vaccine (TCV) offers safe, effective protection against typhoid two years after vaccination in all children, and sustained protection for older children at three to five years post immunisation, according to a report by researchers at the Oxford Vaccine Group and icddr,b. But it also shows a decline in protection at the later timepoints among children vaccinated at younger ages.
New research identifies autoimmunity against a key anti-inflammatory regulator in inflammatory bowel disease
4 August 2024
- Clinical Trials
- Department
- Gastroenterology
- Immunology
- Publication
- Research
- Research Methods
- University
A ground-breaking study, published by the New England Journal of Medicine, has identified a new disease-inducing mechanism for inflammatory bowel disease (IBD) in which the immune system attacks its own regulatory function.
Oxford scientists launch first-in-human vaccine trial for deadly Marburg virus
12 July 2024
Scientists at the University of Oxford have launched a new clinical trial to test a vaccine to protect people against deadly Marburg virus.
New trial launches for two-in-one vaccine to prevent RSV and hMPV
12 July 2024
Scientists at the University of Oxford have launched a phase 1 study to test two investigational mRNA vaccines: one for both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) and a second for RSV alone in infants aged five to eight months old. The vaccines are being developed by Moderna.
Ground-breaking study reveals how COVID-19 vaccines prevent severe disease
3 May 2024
A landmark study by scientists at the University of Oxford, has unveiled crucial insights into the way that COVID-19 vaccines mitigate severe illness in those who have been vaccinated.
New trial to study how the human immune system adapts to ‘tolerate’ malaria parasites
18 March 2024
Scientists at the University of Oxford and the University of Edinburgh have launched a pioneering study that examines how the immune system responds to repeated malaria infections. The BIO-004 study is being run in partnership between the Department of Biochemistry (Draper Lab, based in the Kavli Institute for Nanoscience Discovery), the University of Edinburgh (Spence Lab, Institute of Immunology and Infection Research) and the Oxford Vaccine Group (part of the Department of Paediatrics). BIO-004 will provide a unique insight into how the immune system adapts over the first few malaria infections of life, learning to tolerate malaria parasites and developing natural immunity to severe illness.